title: Tralokinumab for uncontrolled asthma.
abstract: BACKGROUND
  Asthma is a chronic inflammatory disease of the airways mainly related to allergen exposure, in which various cytokine-specific pathways interact among themselves to promote IgE hyperproduction, bronchial hyperresponsiveness, eosinophil local recruitment and airways remodeling. IL-13 is known for its prominent pathogenic role in this disease and therapeutic blocking approaches are underway.
  
  
  METHODS
  Anti-IL-13 antibodies are currently investigated in clinical studies in uncontrolled asthma. Tralokinumab is a human IgG4 anti IL-13 antibody which was recently evaluated in a Phase II study demonstrating the maximal efficacy in a subset of asthma patients characterized by the highest sputum IL-13 levels. The results of this study are discussed in this paper.
  
  
  CONCLUSIONS
  The IL-13 blockade with various therapeutic approaches such as tralokinumab has the potential to improve the asthma control in patients subsets in whom the blocked cytokine is demonstrated to be overexpressed.
authors.affiliation: University of Medicine and Pharmacy, Grigore T Popa Iaşi, Internal Medicine I Clinic, Emergency Hospital Saint Spiridon, Independence Boulevard 1, 700019, Iasi, Romania.
authors.forename: Ileana
authors.initials: I
authors.lastname: Antohe
authors.forename: Rodica
authors.initials: R
authors.lastname: Croitoru
authors.forename: Sabina
authors.initials: S
authors.lastname: Antoniu